Bottom line
Is LFMGX a good fund? The bottom line
LFMGX is the Class F share class of Lord Abbett Micro-Cap Growth Fund, an actively managed small-cap mutual fund from Lord Abbett.
Annual fees run 1.12% — about $112 a year on every $10,000 invested, more expensive than 62% of small-cap funds we track.
It returned +11.0% over one year, +2.0% a year over five years (as of Dec 31, 2025, per its prospectus).
With $213 million in net assets and 86 holdings, its largest position is Cogent Biosciences Inc (2.7%) and the top 10 make up 23.7% of the portfolio.
What stands out
- No front-end sales load
What to watch
- 5-year return in the bottom quarter of its category
- 12b-1 marketing fee of 0.1% a year
- High turnover (107% a year) can mean more taxable distributions
Updated Nov 19, 2026
What LFMGX invests in
The Funds investment objective is long-term capital appreciation.
Under normal conditions, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities of micro-cap companies. A micro-cap company is defined as a company having a market capitalization at the time of purchase that is under $1 billion or falls within the market capitalization range of companies in the Russell Microcap Index. The Fund uses fundamental analysis to look for micro-cap companies that appear to have the potential for more rapid growth than the overall economy. The Fund seeks to identify micro-cap companies that generally exhibit faster-than-average gains in earnings and that the portfolio management team expects to continue profit growth at a high level. The Fund evaluates companies based on an analysis of their financial statements, products and operations, market sectors, and interviews with management.…
From the fund's prospectus (filed Feb 25, 2026).
LFMGX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| LFMGX | +11.0% | +2.0% | — |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What LFMGX costs
On a $10,000 investment, LFMGX's 1.12% expense ratio costs about $112 a year. The prospectus estimates $1,468 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
LFMGX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Cogent Biosciences Inc | 2.75% |
| 2 | Forte Biosciences Inc | 2.65% |
| 3 | Adaptive Biotechnologies Corp | 2.62% |
| 4 | Aehr Test Systems | 2.60% |
| 5 | Navan Inc | 2.54% |
| 6 | Enliven Therapeutics Inc | 2.34% |
| 7 | Lindblad Expeditions Holdings Inc | 2.12% |
| 8 | Fixed Income Clearing Corp. | 2.08% |
| 9 | Fidelity Investments | 2.03% |
| 10 | CECO Environmental Corp | 1.99% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 23.7% of the fund. See all top 25 holdings and asset mix →